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Abstract: Biodistribution of nanoparticles is dependent on their physicochemical properties 
(such as size, surface charge, and surface hydrophilicity). Clear and systematic understanding 
of nanoparticle properties’ effects on their in vivo performance is of fundamental significance 
in nanoparticle design, development and optimization for medical applications, and toxicity 
evaluation. In the present study, a physiologically based pharmacokinetic model was utilized 
to interpret the effects of nanoparticle properties on previously published biodistribution data. 
Biodistribution data for five poly(lactic-co-glycolic) acid (PLGA) nanoparticle formulations 
prepared with varied content of monomethoxypoly (ethyleneglycol) (mPEG) (PLGA, PLGA-
mPEG256, PLGA-mPEG153, PLGA-mPEG51, PLGA-mPEG34) were collected in mice 
after intravenous injection. A physiologically based pharmacokinetic model was developed 
and evaluated to simulate the mass-time profiles of nanoparticle distribution in tissues. In 
anticipation that the biodistribution of new nanoparticle formulations could be predicted 
from the physiologically based pharmacokinetic model, multivariate regression analysis was 
performed to build the relationship between nanoparticle properties (size, zeta potential, and 
number of PEG molecules per unit surface area) and biodistribution parameters. Based on these 
relationships, characterized physicochemical properties of PLGA-mPEG495 nanoparticles 
(a sixth formulation) were used to calculate (predict) biodistribution profiles. For all five initial 
formulations, the developed model adequately simulates the experimental data indicating that 
the model is suitable for description of PLGA-mPEG nanoparticle biodistribution. Further, the 
predicted biodistribution profiles of PLGA-mPEG495 were close to experimental data, reflecting 
properly developed property–biodistribution relationships.
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Introduction
It is well established that adjusting nanoparticle properties such as size and surface charge 
can modify the biodistribution of nanoparticles. Optimized nanoparticle formulations 
with specific distribution (targeting) within the body for medical applications, including 
drug delivery and cancer diagnosis, are highly sought. Many chemicals, polymers, 
preparation methods, and surface ligands have been, and are currently being, developed 
to specifically achieve high nanoparticle accumulation in target tissues such as tumors. 
However, it is not explicitly clear how nanoparticle properties influence nanoparticle 
absorption, distribution, metabolism, elimination, and toxicity. Quantitative methods 
beyond pharmacokinetics of the therapeutic are needed to describe and predict the 
effects of nanoparticle properties on in vivo performance. Without clear understanding 
of such property-absorption/distribution/metabolism/elimination relationships, the 
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effects of any property modification can only be tested 
with animal experimentation, which is resource (time and 
cost) intensive. Considering the numerous materials and 
methods for nanoparticle preparation, it is impractical to 
screen them all in vivo. Rational methodologies are urgently 
needed to assist in the evaluation of nanoparticle targeting/
biodistribution and analysis of available data for optimization 
and designation of nanoparticles.
Biodistribution of nanoparticles is determined by their 
properties when other conditions are held constant (ie, animal 
models and administration routes). Therefore, relationships 
should exist between nanoparticle properties and biodistri-
bution, similar to the quantitative structure-activity relation-
ships of chemical molecules.1 Specific description of such 
relationships would greatly aid the design of nanoparticles 
for medical applications. Although numerous studies have 
qualitatively proven the existence of such relationships,2 no 
work to date has defined them with quantitative analysis. To 
build such quantitative relationships, the biodistribution of a 
series of nanoparticle formulations should be obtained. Both 
nanoparticle properties and biodistribution need to be quanti-
fied for mathematical description of nanoparticle property–
biodistribution relationships. Nanoparticle properties are 
relatively easy to measure, although the required degree 
and type of characterization is still not well established.3 It 
is much more difficult to quantify biodistribution. Generally, 
biodistribution is reported as nanoparticle tissue concentra-
tions or nanoparticle mass in tissues at various terminal 
time points. It is difficult to compare such static and isolated 
data points among different studies, especially when differ-
ent study designs are used (ie, nanoparticle doses, animal 
models, administration routes, and sampling time points). 
A more rational method should be adopted for quantifying 
biodistribution kinetic profiles, and physiologically based 
pharmacokinetic (PBPK) models may prove to be the ideal 
tool for this purpose.4
PBPK models list tissues and organs as individual 
compartments and the nanoparticle transportation among 
them is described by mathematical rate equations. With 
PBPK   modeling, biodistribution is quantified using a set 
of parameters, which are only dependent on   nanoparticle 
properties, but relatively independent to study design. 
These parameters can then be more easily compared 
among   different studies. PBPK models have been used 
for simulation of the biodistribution of small chemical 
  molecules for more than 30 years,4 and have advantageously 
been used in toxicity and biodistribution studies. A specific 
application with   demonstrated success is the building of 
structure-  pharmacokinetic relationships5 that quantitatively 
correlate the chemical structures of drugs to their pharma-
cokinetic profiles. Similarly, the authors believe they may be 
used to build the relationships between nanoparticle proper-
ties and their biodistribution.
Initially, fitting experimental biodistribution data into 
the PBPK model can generate a set of parameters. The 
parameters can then be correlated to nanoparticle properties 
by mathematical equations. These equations could be used 
to analyze the contributions of nanoparticle properties to 
individual transportation processes within the body. Apart 
from aiding the understanding of nanoparticle property 
effects on biodistribution, such property–biodistribution 
relationships could have further applications. For example, 
biodistribution kinetic parameters of new nanoparticle 
formulations could be calculated based on their properties 
and used for the prediction of their biodistribution. These 
relationships could also guide designation of nanoparticles 
with particular properties in order to quantitatively control 
their biodistribution for specific applications.
The application of PBPK models to nanoparticle 
biodistribution studies is a recently emerging field, as 
was discussed in greater detail in a recent review.6 It is 
more difficult to build PBPK models for nanoparticles 
than for small molecules due to distinct differences in 
their physiological processes within the body. Despite the 
limited application of PBPK models to nanoparticles (and 
the limited complexity of the models used to date), PBPK 
modeling has great potential in nanoparticle research. In one 
such work, Lankveld et al7 use PBPK modeling to compare 
the distribution kinetics of silver nanoparticles of different 
sizes. Although this work represents the only study to date 
that defines a quantitative relationship between a nanoparticle 
property (size) and tissue kinetics, no significant relationship 
could be determined despite significant differences in the 
experimental data. Lankveld et al hypothesized that other 
properties, such as surface properties, were key determinants 
of biodistribution kinetics.
In a previous study, the biodistribution of five nanoparticle 
formulations prepared with poly(lactic-co-glycolic) acid 
(PLGA) with varied content of monomethoxypoly (ethylene-
glycol) (mPEG) (PLGA, PLGA-mPEG256, PLGA-mPEG153, 
PLGA-mPEG61, and PLGA-mPEG34) was investigated.8 
Physicochemical properties of these nanoparticle formula-
tions (size, surface charge, and surface PEG content) varied as 
a function of mPEG content. It was demonstrated that distri-
bution of these nanoparticles is influenced by their properties. 
Here, a PBPK model is used to explain the in vivo behavior 
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of these nanoparticle formulations, and furthermore, establish 
quantitative relationships between nanoparticle properties 
and biodistribution. These relationships were then used to 
predict biodistribution of a sixth nanoparticle formulation 
(PLGA-mPEG495).
Materials and methods
Experimental data
Most of the experimental data used in this study, and the 
characterization of the described nanoparticles, has been 
reported elsewhere.8 The tissue distribution of the 125I-CA 
(5-cholesten-3-[N-phenyl]amine) label and the  125I-CA-
labeled PLGA and PLGA-mPEG nanoparticles was 
determined in female Swiss-De mice weighing 25–30 g. The 
animals, three per group, were injected in the tail vein with 
100 µL of nanoparticles (300 µg polymer per mouse). At 0, 
0.033, 0.5, 1, 3, and 6 hours, the mice were sacrificed and 
their tissues (liver, spleen, lungs, muscle, bone – femur of 
left hind leg, intestines, kidney, urinary bladder, brain, and 
thyroid) were excised. Tissues were then quickly washed 
with cold water to remove surface blood, and counted for 
radioactivity. Blood samples (0.07–0.08 g) were obtained 
in duplicate by cardiac puncture in preweighed heparinized 
tubes. The radioactivity remaining in the tail was also 
measured and taken into consideration in the calculation of 
total radioactivity dose administered to the animals. In the 
calculations of the percentage dose per organ, blood, bone, 
and muscle were considered to constitute the 7%, 10%, and 
43% of the body weight, respectively.9
In a previous paper,8 the authors reported the mass-time 
courses of blood, liver, spleen, bones, muscles, intestine, 
lungs, and urine. Some other tissues with lower distribution 
were not presented (kidneys, thyroid, stomach, and brain), 
but are included here. To be consistent with the experiments, 
the data in each compartment are presented as percentage of 
initial dose. As nanoparticle recovery from the experiments 
was very good (more than 95% of initial dose, Table 1), it is 
assumed that no significant distribution occurred into other 
tissues that were not tested.
PBPK model development and evaluation
The first step of PBPK model building is to determine the 
organs and tissues to be identified as compartments. Based 
on the experimental data, the whole body was divided 
into seven compartments (blood, lungs, gastrointestinal 
tract (GI), liver, spleen, kidneys, and body) with the blood 
  connecting all compartments. The liver and spleen were the 
major organs for nanoparticle distribution in previous work.8 
A GI lumen compartment was included for nanoparticles 
excreted through bile, and the kidney compartment includes 
a subcompartment for urine excretion. The remaining organs 
and tissues were combined into one compartment named the 
body (bones, muscles, thyroid, and brain). It was assumed 
that degradation did not occur within the relatively short time 
period of experiments (6 hours).
Experimentally, bile-excreted nanoparticles were not 
separated from those within the GI tissue. To evaluate bile 
excretion, the data should be divided. Because the mass 
of nanoparticles in the GI was low for all nanoparticle 
formulations (the highest value was 6.15%), both the 
distribution into GI tissue and bile excretion must be lower 
than that, and thus have little influence on the distribution 
of other tissues. Based on this consideration, nanoparticles 
in the GI were first considered as all in GI tissue without 
any bile excretion (no nanoparticles in GI lumen). With 
model simulation, predicted values of each time point were 
obtained. Then the experimental data were considered as 
solely bile excretion (all nanoparticles in GI lumen), and 
predicted values generated again with model simulation. 
The ratio of the simulated values at each time point 
from both simulations was calculated and experimental 
data were normalized by the ratio and used for the final 
simulation.
PBPK models are generally divided into two groups 
according to transportation mechanisms: blood flow-limited 
and membrane-limited models.4 The blood flow-limited 
model assumes that every organ is a well-stirred compartment 
and nanoparticle distribution between blood and tissue 
instantly reaches equilibrium. The only factor limiting the 
transportation between blood and tissue is the blood flow 
rates for each tissue. For membrane-limited models, it is 
assumed that transportation between blood and tissue is 
limited by permeability of the blood capillary membrane or 
tissue cell membrane. In this case, only the blood capillary 
Table  1  Dose  recovery  of  poly(lactic-co-glycolic)  acid  and 
poly(lactic-co-glycolic) acid- monomethoxypoly (ethyleneglycol) 
nanoparticles at various time points
Formulations Time (hours)
0.033 0.5 1 3 6
PLGA 98.00 98.00 97.98 96.27 97.96
PLGA-mPEG256 97.96 98.02 97.97 97.99 97.98
PLGA-mPEG153 97.84 99.13 97.99 97.92 98.01
PLGA-mPEG61 97.96 99.82 98.02 97.40 98.03
PLGA-mPEG34 94.00 97.98 96.30 98.01 97.93
Abbreviations:  mPEG,  monomethoxypoly  (ethyleneglycol);  PLGA,  poly(lactic- 
co-glycolic) acid.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1347
PBPK modeling of PLGA-mPEG nanoparticlesInternational Journal of Nanomedicine 2012:7
wall and/or cellular barriers determine transportation of 
nanoparticles between blood and tissue.
Both blood flow-limited and membrane-limited models 
were both built in this work (the structures of these models 
are presented in Figure 1), and evaluated for how well the 
experimental data can be simulated by each as follows:
  
(1)
Equation 1 evaluates the differences between estimated 
data and observed data as described previously.9 An R2 value 
close to unit means the best prediction of the experimental 
data by the model.
For all five formulations, the membrane-limited model 
performed better than the blood flow-limited model (Table 2). 
As a result, the membrane-limited model was selected for all 
other work described in this study.
Mass transfer rate equations  
and parameter optimization
Rate equations for each compartment were obtained using 
the basic principle of mass balance conservation: the net 
amount of nanoparticles in the organ must equal the sum of all 
nanoparticles that enter the organ minus all nanoparticles that 
leave the organ. For this type of model, a single mass balance 
differential equation describes the nanoparticle distribution for 
each separate organ as shown in the following equation:
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where Cp and Mp refer to the nanoparticle concentration and 
amount in the blood, Ci, Mi, Ri, ki, Vi, and CLi refer to the nano-
particle concentration, nanoparticle amount, tissue–blood 
partition coefficient, diffusion coefficient, tissue volume, 
and excretion coefficient in tissue i, respectively. For tissues 
that have no excretion, the CLi will be zero. Nanoparticle 
amounts in tissues were obtained from experimental data as 
previously described. Tissue volume values were collected 
from the literature.10
The mass balance equation for the blood compartment is:
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Parameter optimizations were performed with MATLAB® 
software (version R2009a; Mathworks, Natick, MA) using 
the least square optimization method with all parameters 
estimated simultaneously. This is a commonly used method 
for nonlinear curve fitting. The diffusion coefficients and 
partition coefficients were allowed to vary within limitations, 
which were determined as described below.
An open-loop method was first carried out to calculate 
the initial values of diffusion coefficients for final estimation. 
The blood mass-time data were fitted into a biexponential 
function:
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where A and B are the intercepts for each exponential   segment 
of the blood mass-time curve. Equation 4 describes the blood 
mass-time profile and serves as a forcing function.11 It was 
held constant in the PBPK model and used as the input 
function to fit the nanoparticle values for each compartment 
individually, allowing values for the diffusion coefficients 
to be obtained and used as the initial values for further 
optimization.
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Figure 1 Schematic diagrams of the blood flow-limited model (A) and the membrane-
limited model (B). Arrows indicate the transportation of nanoparticles with the dashed 
arrows in (B), indicating differing transportation equations from solid arrows in (A).
Note: Triangles represent the intravenous administration.
Abbreviation: GI, gastrointestinal tract.
Table  2  Evaluation  of  physiologically  based  pharmacokinetic 
model structures for nanoparticle formulations (R2)
Formulations Blood flow-limited Membrane-limited
PLGA 0.9528 0.9947
PLGA-mPEG256 0.4408 0.9856
PLGA-mPEG153 0.4129 0.9935
PLGA-mPEG61 0.5970 0.9855
PLGA-mPEG34 0.8718 0.9708
Abbreviations: mPEG, monomethoxypoly (ethyleneglycol); PLGA, poly(lactic-co-
glycolic) acid.
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Initial values for excretion coefficients were also 
  estimated. The accumulation of nanoparticles excreted from 
the kidney compartment is expressed as:
  dM
dt
CL M
urine
kidneyk idney =   (5)
where Murine is the accumulated nanoparticle mass in the urine, 
CLkidney is the excretion coefficient for the kidney, and Mkidney 
is the nanoparticle mass in kidney at time t. To calculate the 
initial excretion value, the average nanoparticle mass in the 
kidney compartment ( Mkidney) during the entire study period 
(0–6 hours) was used. As  Mkidney is a constant, the above 
equation converts to:
  MC LMt urinek idneyk idney =   (6)
Experimental data was fit into this linear equation 
to calculate the initial excretion value from the kidney 
  compartment (kCL,kidney). The initial value of the liver   excretion 
coefficient was estimated the same way.
First, upper and lower limitations of diffusion and 
excretion coefficients were determined. The lower 
limitation was set at zero (all values are positive). The 
upper limits of diffusion coefficients were determined based 
on blood flow rates from the literature,10 considering that 
nanoparticle distribution from blood into tissues could not 
be faster than the rate at which blood carries nanoparticles 
into that tissue. Similar upper limits were set for excretion 
coefficients:
  k
Q
V
i
i
p
≤   (7)
where Qi is the blood flow rate of tissue i and Vp is the   volume 
of plasma.
With the initial values determined, a closed-loop 
method was used to globally estimate all the parameters 
simultaneously for each of the five nanoparticle   formulations. 
The model parameters were adjusted by the software to 
minimize the difference between simulated values and 
experimental data points.
PBPK model implementation
After the parameters were determined, the mathematical 
  equations describing the mass-time profiles of the five 
  nanoparticle formulations were programmed into the 
MATLAB software. Simulation was then carried out   producing 
  mass-time curves for comparison with experimental data.
Sensitivity analysis
Some model parameters may be more sensitive than others 
in shaping the mass-time profiles of the tissue   compartments. 
Slight changes in these parameters could result in sig-
nificant changes in the simulated nanoparticle distribution. 
  Identification and consideration of these sensitive parameters 
is needed when optimizing nanoparticle biodistribution simu-
lation. As the general purpose of PEG-modified nanoparticles 
is to increase blood circulation time, sensitivity analysis was 
evaluated using the area under the curve (AUC) of blood 
from time zero to 6 hours. To test sensitivity, the value of an 
individual parameter was increased by 1%, model simulations 
repeated, and the blood AUC recalculated. This process was 
done for each parameter of the model. Relative sensitivity 
coefficients for all parameters were calculated using the 
following equation:11
  Sensitivity
dAUC dk
AUCk
=
/
/
  (8)
ie, the percentage change in AUC divided by the percentage 
change in the parameter k.
Correlation of diffusion coefficients  
with nanoparticle properties
Although biodistribution is determined by many individual 
nanoparticle properties, it is difficult to interpret the 
interplay of multiple properties and how these influence 
the interaction between nanoparticles and the human 
body. Since multiple properties simultaneously determine 
individual transportation parameters, they should be 
evaluated simultaneously for individual in vivo processes. 
For example, both surface charge and size have each been 
shown to influence liver excretion of nanoparticles.12–14 
Given this, it would be difficult to reach clear conclusions 
by correlating transportation parameters to a single 
nanoparticle property. A commonly used method to analyze 
the influence of more than one independent variable on a 
single dependent property is multivariate regression.15 With 
multivariate regression analysis, the effects of multiple 
properties on one particular parameter can be simultaneously 
evaluated.15 Currently, there is little known about how 
nanoparticle properties affect individual transportation 
kinetic parameters. Reported here for the first time is a linear 
multivariate regression between each parameter and three 
nanoparticle properties.
The nanoparticle properties (size, zeta potential, NPEG) 
evaluated are listed in Table 3. NPEG is the number of PEG 
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molecules per unit surface area as previously reported. The 
equation for each parameter takes the following format:
  kA xB xC xI ntercept =+++ 123   (9)
where x1, x2, and x3 are nanoparticle size, zeta potential, 
and NPEG values, and A, B, and C are the constants to be 
estimated.
Prediction of biodistribution profiles  
of PLGA-mPEG495 nanoparticles
Once the relationship between nanoparticle properties and 
an individual transportation parameter is established, the 
value of that parameter for specific nanoparticle properties 
is predictable. For a nanoparticle formulation of known 
properties, all necessary parameters for the PBPK model 
can be calculated resulting in a predicted simulation of the 
biodistribution mass-time curves.
Here, the parameters for PLGA-mPEG495 nanoparticles 
from its properties were calculated (Table 3) and the 
  property-distribution relationship equations generated 
above. These parameters were then used to simulate the 
biodistribution profiles using the membrane-limited model 
structure. PLGA-mPEG495 nanoparticles were then tested 
for their biodistribution at 3 hours and compared with 
  predicted values.
Results
PBPK model development and evaluation
Both blood flow-limited and membrane-limited models were 
analyzed to determine which could best simulate nanoparticle 
biodistribution data. It was found that the membrane-limited 
model performed better for all five formulations (Table 2). 
For PLGA nanoparticles without PEG, the blood flow-limited 
model also fit experimental data well (R2 values were 0.9528 
and 0.9947 for the blood flow-limited and the membrane-
limited models, respectively). This is in agreement with 
experimental results of rapid blood clearance of PLGA 
nanoparticles compared to mPEG-containing nanoparticles. 
However, for all nanoparticle formulations with mPEG, 
the R2 values for the blood flow-limited model were much 
lower. This indicates that the blood to tissue distribution of 
nanoparticle formulations is largely membrane-limited rather 
than blood flow-limited.
Parameter estimation and analysis
Parameters generated from PBPK model simulation 
  (membrane-limited) are listed in Table 4, including   diffusion, 
tissue–blood partition, and excretion coefficients. Higher 
diffusion coefficients mean faster transportation rates of 
nanoparticles from blood into tissues, and higher   excretion 
coefficients (urine and bile) represent faster clearance 
rates of nanoparticles from the kidneys and liver. Higher 
partition coefficients indicate nanoparticles have higher 
resident time within tissue than within blood, which leads 
to slower transportation rates from tissues back into blood 
circulation.
In general, all parameters were significantly   different 
for PLGA nanoparticles compared to PEG-containing 
nanoparticles. For all nanoparticles, both diffusion 
and partition coefficients were highest in liver, kidney, 
and body, but lowest in lung (except PLGA-mPEG34), GI, 
Table 3 Nanoparticle properties
Formulations Size (nm) Zeta (mV) NPEG (nm-1)
PLGA 133.5 ± 20.1 -54.2 0
PLGA-mPEG495 114.8 ± 11.1 -6.2 0.36
PLGA-mPEG256   97.4 ± 3.5 -5.9 0.5
PLGA-mPEG153   79.0 ± 14.2 -4.7 0.59
PLGA-mPEG61   67.0 ± 6.6 -5.2 0.71
PLGA-mPEG34   57.5 ± 17.3 -4.3 0.77
Abbreviations: mPEG, monomethoxypoly (ethyleneglycol); NPEG, number of poly 
(ethyleneglycol) molecules per unit surface area; PLGA, poly(lactic-co-glycolic) acid.
Table 4 Diffusion, partition, and clearance coefficients in the membrane-limited model
Formulations Diffusion coefficients (h-1) Tissue–blood partition coefficients  
(unitless)
Excretion 
coefficients 
(h-1)
Lung GI Liver Spleen Kidney Body Lung GI Liver Spleen Kidney Body Bile Urine
PLGAa 4.25 4.71 2.84 1.78 63.0 3.51 1.80 2.47 2.75 0.27 5.93 1.07 0.007 0.52
PLGA-mPEG256a 7.20 125.18 2.02 59.95 0.27 0.21 6.70 13.86 0.25 0.39 0.05 0.01 0.015 0.013
PLGA-mPEG153a 6.47 172.34 1.12 53.29 0.27 0.98 4.31 3.36 0.29 0.53 0.12 0.07 0.058 0.0096
PLGA-mPEG61a 9.30 159.52 2.08 59.95 0.20 0.30 3.29 4.18 0.38 0.46 0.29 0.08 0.064 0.0034
PLGA-mPEG34a 3.27 36.62 1.91 27.93 2.66 1.02 2.67 2.59 0.45 0.55 0.10 0.12 0.041 0.019
PLGA-mPEG495b 8.35 194.95 1.48 73.04 1.12 0.25 13.93 12.05 0.19 0.39 0.45 0.01 0.07 0.0085
Notes: aEstimated from physiologically based pharmacokinetic modeling; bcalculated from equations developed through multivariate regression.
Abbreviations: GI, gastrointestinal tract; mPEG, monomethoxypoly (ethyleneglycol); PLGA, poly(lactic-co-glycolic) acid.
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and spleen. For PLGA nanoparticles, bile excretion was 
  lowest and renal excretion was highest. The high renal excre-
tion of PLGA nanoparticles is consistent with experimental 
data, but bile excretion is new information generated from 
the model. The high renal excretion of PLGA, which had the 
largest size among all nanoparticle formulations, indicates 
that size may not be the most important factor in determina-
tion of nanoparticle clearance from kidneys, for the formula-
tion in this study. On the other hand, low bile excretion of 
nanoparticles indicates that liver excretion of nanoparticles 
may be determined by nanoparticle properties in a different 
pattern from that of renal excretion.
Parameters for the PEG-containing nanoparticle formu-
lations were relatively close to each other and there were 
no obvious linear relationships between PEG content and 
individual parameters. For most parameters, values changed 
irregularly with increasing PEG content. This may be a result 
of the interplay between multiple properties. Generally, with 
increased PEG content, the size reduced and surface charge 
became less negative. The contribution of increased PEG 
content to the change in PBPK model parameters could be 
reduced (or even reversed) by the effects of reduced size and/
or less negative surface charge. One interesting   observation 
is that excretion rates from the liver and kidneys were 
opposite (ie, high liver excretion occurred simultaneously as 
low renal excretion and vice versa) for all five nanoparticle 
formulations, indicating that the effects of nanoparticle prop-
erties on liver excretion oppose renal excretion. For example, 
PLGA-mPEG153 and PLGA-mPEG61 nanoparticles had the 
highest liver excretion rates, but the lowest renal excretion 
rates. This cannot be explained by any of the three properties 
separately, because for all properties (size, zeta potential, 
NPEG), PLGA-mPEG61 nanoparticles were in the middle 
among the five formulations.
Simulation of experimental data
Although both the blood flow-limited model and membrane-
limited model were evaluated, only simulation results 
using the later are shown. Simulation was compared with 
experimental data as shown in Figure 2. Parameters, including 
transportation coefficients and partition coefficients, used 
in this simulation are shown in Table 4. There is good 
consistency between simulated and experimental data, 
indicating the parameters have been properly estimated 
and the model is suitable in interpreting the experimental 
data. The simulated curves fit the experimental data best for 
tissues with high nanoparticle levels (blood, liver, and body). 
For tissues with low nanoparticle levels (lungs, GI, kidney, 
and spleen), the simulated curves are less consistent with 
experimental data. This is because the model is less sensitive 
to lower nanoparticle levels.
The simulated profiles show that the increased blood 
circulation time of PEG-containing nanoparticles   primarily 
results from reduced liver and spleen distribution.   Considering 
the volume of spleen (0.1 g for mice), the relative concentrations 
were high. For other tissues (lungs, kidneys, body, and GI), 
there was no significant difference between PLGA- and PEG-
containing nanoparticle formulations. This is in agreement 
with the understanding that PEG modification of nanoparticles 
reduces the uptake by the reticuloendothelial system, which 
is primarily in the liver and spleen.16
From the simulated profiles of the five nanoparticle 
formulations, it is obvious that most of the nanoparticles 
distribute into tissues within the initial minutes after 
administration. For PLGA nanoparticles, the major portion 
of distribution was complete within a few minutes, and 
distribution reached steady-state in less than half an 
hour. For PEG-containing nanoparticle formulations, the 
distribution reaches steady-state within half an hour in 
lungs, GI, and kidneys, but there is a continual increase (no 
steady-state) in liver, body, and spleen. The significant and 
slower distribution into the body compartment could be 
due to two reasons: first, the body compartment includes 
muscles and bones, having a much larger volume than other 
compartments; and second, macrophages in bone marrow 
may actively uptake nanoparticles.
Simulated bile and renal excretion is shown in Figure 3. 
For renal excretion, there is good agreement between 
simulated curves and experimental results. For bile excretion, 
the simulation fit cannot be determined as no experimental 
data exists for comparison. The PLGA nanoparticles showed 
much higher renal excretion, but lower bile excretion than 
PEG-containing nanoparticles. Among the PEG-containing 
nanoparticle formulations, there were no relationships 
between PEG content and bile or renal excretion. This is 
consistent with the trend of the excretion coefficients as 
discussed above.
Sensitivity analysis
Sensitivity analysis results are listed in Table 5. Positive 
values refer to an increase in the blood AUC when the 
parameter increases and negative values refer to a decrease in 
the blood AUC when the parameter increases. The influence 
of parameters on all five formulations was similar, and the 
most influential parameters were diffusion coefficients and 
partition coefficients of the kidneys and body compartments. 
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Figure  2  Simulation  of  experimental  data  using  the  membrane-limited  model.  (A)  poly(lactic-co-glycolic)  acid,  (B),  poly(lactic-co-glycolic)  acid-monomethoxypoly 
(ethyleneglycol)256,  (C)  poly(lactic-co-glycolic)  acid-monomethoxypoly  (ethyleneglycol)153,  (D)  poly(lactic-co-glycolic)  acid-monomethoxypoly  (ethyleneglycol)61,  and   
(E) poly(lactic-co-glycolic) acid-monomethoxypoly (ethyleneglycol)34 nanoparticles.
Note: Dots represent experimental data and lines represent simulated mass-time curves.
Abbreviations: GI, gastrointestinal tract; ID, initial dose.
Although liver had the highest accumulation, kinetic 
parameters into and out of it were not the most influential.
Property–biodistribution relationship 
and prediction of PLGA-mPEG495 
biodistribution
Regression-generated values of relationship constants are listed 
in Table 6. Although no obvious linear relationships were found 
between an individual property and biodistribution parameters, 
the multivariate regression analysis resulted in good linear 
relationships for most parameters (an R2 value, the coefficient 
of determination, close to unit indicates a good relationship). 
For a few parameters, including the diffusion coefficient of 
liver (0.6664), tissue–blood partition coefficient of GI (0.6341), 
and renal excretion coefficient (0.7522), the R2 values were 
relatively lower and the linear relationship was moderate.17
The estimated relationships were used to calculate 
transportation parameters according to equation (9) for 
PLGA-mPEG495 nanoparticles. The biodistribution profiles 
of PLGA-mPEG495 nanoparticles were then simulated using 
the membrane-limited PBPK model. Predicted distribution 
profiles are presented in Figure 4. Experimental data for 
PLGA-mPEG495 nanoparticles (at 3 hours for all tissues) 
were compared with predicted values. It was found that 
the predicted values for PLGA-mPEG495 were close to 
experimental data for all tissues (Figure 4).
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Discussion
PBPK modeling was used to analyze the biodistribution 
of PLGA-mPEG nanoparticles with various PEG content. 
Kinetic parameters were estimated and analyzed to under-
stand the influence of particle properties (size, surface charge, 
and PEG content) on biodistribution parameters. Based on 
the optimized transportation and tissue–blood partition 
  coefficients, the mass-time profiles in individual tissues of 
five nanoparticle formulations were simulated. The estimated 
parameters were then correlated to nanoparticle properties 
mathematically, and used to calculate the kinetic   coefficients 
for PLGA-mPEG495 to predict the biodistribution. By 
  simulating the biodistribution of five nanoparticle for-
mulations using a PBPK model, the aim was to further 
understand the mechanisms of nanoparticle biodistribution 
and the relationships between nanoparticle properties and 
biodistribution. Deeper insight into these issues could be 
very helpful in further studies of nanoparticle applications 
and formulation design.
PBPK modeling has been applied to various types of 
nanoparticles.7,18–20 In these previous works, blood flow-
limited models were used. A blood flow-limited model 
assumes that the nanoparticle concentrations in blood and 
tissues instantly reach equilibrium, thus, the transportation 
rate of nanoparticles from blood into tissues is dependent 
solely on blood flow rates. However, such an assumption, 
in some cases, did not result in very satisfactory simulation 
of experimental data. As has been reported, the blood clear-
ance half-life of nanoparticles of various components and 
properties could range from minutes to hours.6 Therefore, 
nanoparticle distribution from blood to tissues is likely slower 
than most small chemical molecules, and may not be depen-
dent on blood flow rates. To obtain satisfactory simulation 
of experimental data, model structures can be evaluated first 
for proper model selection. In this study, after evaluation of 
two model types, it was confirmed that a membrane-limited 
model should be adopted. The evaluation results also indi-
cate that for PLGA nanoparticles, which were cleared most 
quickly from the blood, a blood flow-limited model will also 
adequately simulate the experimental data.
Apart from transportation mechanisms, the structures of 
the PBPK models also need to be carefully selected. There are 
no well-established rules for determination of PBPK model 
structures and it may depend on both the available data and 
knowledge in the general area. More complicated PBPK 
structures have been utilized20 with more compartments 
and subcompartments. However, much more data need 
to be collected to support the parameter estimation, and, 
in some cases, this may not be feasible. Evaluation of the 
model structure is a critical factor in all PBPK models of 
Table 5 Sensitivity analysis of biodistribution parameters in blood area under the curve of poly(lactic-co-glycolic) acid and poly(lactic-
co-glycolic) acid-monomethoxypoly (ethyleneglycol) nanoparticles
Formulations Diffusion coefficients Tissue–blood partition coefficients Excretion 
coefficients
Lung GI Liver Spleen Kidney Body Lung GI Liver Spleen Kidney Body Bile Urine
PLGA -0.033 0.031 -0.055 0.049 -0.649 0.623 -0.043 0.039 -0.067 0.032 -0.114 0.108 -0.014 -0.201
PLGA-mPEG256 -0.027 0.027 -0.016 0.016 -0.325 0.116 -0.022 0.008 -0.041 0.030 -0.141 0.058 -0.050 -0.059
PLGA-mPEG153 -0.023 0.023 -0.013 0.013 -0.159 0.121 -0.015 0.015 -0.038 0.038 -0.129 -0.016 -0.016 -0.012
PLGA-mPEG61 -0.030 0.0 -0.018 0.018 -0.194 0.085 -0.022 0.022 -0.033 0.032 -0.176 0.128 -0.012 -0.009
PLGA-mPEG34 -0.019 0.019 -0.015 0.015 -0.509 0.424 -0.038 0.037 -0.031 0.030 -0.169 0.166 -0.017 -0.014
Abbreviations: GI, gastrointestinal tract; mPEG, monomethoxypoly (ethyleneglycol); PLGA, poly(lactic-co-glycolic) acid.
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Figure 3 Simulation of renal (A) and bile (B) excretion for poly(lactic-co-glycolic) acid and poly (ethyleneglycol)-containing nanoparticle formulations. 
Notes: For renal excretion, dots represent experimental data. Data for bile excretion from the original experimental do not exist.
Abbreviations: ID, initial dose; mPEG, monomethoxypoly (ethyleneglycol); PLGA, poly(lactic-co-glycolic) acid.
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nanoparticles. In this study, tissues with very low levels of 
nanoparticle distribution are not listed as individual compart-
ments (brain and thyroid).8 This is based on the understanding 
that parameter estimation for tissues with very low levels 
of distribution may result in high error, which may mislead 
interpretations.
The developed model simulated the experimental data 
quite well for all five nanoparticle formulations. The simu-
lated results indicated that for all five formulations, there was 
a very fast initial distribution phase and then later a slower 
distribution phase. The fast initial distribution could be due to 
the blood circulation carrying nanoparticles into every tissue, 
while the later slower phase is more likely determined by the 
properties of each tissue. This may explain redistribution of 
nanoparticles among tissues. The data shows that after the 
initial distribution phase, nanoparticle concentrations in some 
compartments such as lungs and GI continually reduced, 
indicating particle redistribution into other tissues such as 
liver, spleen, and body (containing bone marrow). For PEG-
containing nanoparticle formulations, blood nanoparticle 
concentration remained high for many hours without further 
significant distribution into lungs, GI, and kidneys. This is 
consistent with previous studies, which show a rapid low-
level distribution of PEG-modified nanoparticles initially, and 
then a slow decrease in levels for most tissues.21
However, in vitro cellular models have shown endothelial 
cell uptake of PLGA nanoparticles, with various capacities 
in different cell types,22–24 with uptake half-lives much more 
than a few minutes or even hours.25,26 These contradicting 
findings indicate that there are tremendous differences 
between in vivo and in vitro nanoparticle kinetics. The com-
plexity of in vivo behavior may not be easily represented by 
cellular models.
Besides systemically explaining nanoparticle biodistribu-
tion, kinetic parameters estimated by the PBPK model may 
provide quantitative evaluation of the effects of nanoparticle 
properties on their interaction with individual tissues. It was 
found that most of the parameters of PLGA were   significantly 
different from those of PEG-containing nanoparticles, 
indicating different distribution kinetics. However, no clear 
trends were found in kinetic parameters with increasing PEG 
content among PEG-containing nanoparticles. This could 
be due to the influence of other properties (size, surface 
charge), which also changed with increased PEG content. 
Based on this consideration, the authors tried to correlate 
all three nanoparticle properties with the kinetic   parameters. 
The   multivariate regression-generated linear   relationships 
between nanoparticle properties and biodistribution 
parameters provided a good fit for most parameters. For 
some parameters, the relationships were moderate, and the   
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Figure 4 Predicted biodistribution kinetic profiles of poly(lactic-co-glycolic) acid-monomethoxypoly (ethyleneglycol) 495 nanoparticles (A) and comparison of experimental 
and predicted values of tissue distribution of poly(lactic-co-glycolic) acid-monomethoxypoly (ethyleneglycol) 495 nanoparticles at 3 hours (B).
Abbreviations: GI, gastrointestinal tract; ID, initial dose.
Table 6 Relationship equations of nanoparticle properties and biodistribution kinetic parameters
Diffusion coefficients Tissue–blood partition coefficients Excretion 
coefficients
Lung GI Liver Spleen Kidney Body Lung GI Liver Spleen Kidney Body Bile Urine
Intercept -42.17 833.70 -22.18 -152.23 23.88 21.03 -6.06 773.98 -71.39 -1041.7 36.44 164.07 0.40 0.23
A (size) 0.32 -2.97 0.14 1.60 -0.20 -0.13 0.03 -4.57 0.50 8.10 -0.21 -0.80 0.002 -0.002
B (zeta) 0.07 -7.97 0.13 -1.09 1.22 0.0 0.09 -2.98 0.11 -0.60 0.04 -1.00 0.003 0.01
C (NPEG) 38.02 -695.02 20.38 136.76 -22.33 -16.57 8.04 -600.66 60.42 846.20 -28.60 -138.81 -0.33 -0.21
R2 0.9968 0.9059 0.6664 0.9993 0.9999 0.9604 0.9284 0.6341 0.9999 0.8784 0.9999 0.9981 0.7522 0.9990
Abbreviations:  GI,  gastrointestinal  tract;  mPEG,  monomethoxypoly  (ethyleneglycol);  NPEG,  number  of  poly  (ethyleneglycol)  molecules  per  unit  surface  area;   
PLGA, poly(lactic-co-glycolic) acid.
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following explanations are hypothesized. First, the high inher-
ent variability and complexity of biological systems result 
in uncertainty in experimental results.4 Variation of experi-
mental data directly influences the precision of parameter 
estimation, and further, the property–  biodistribution rela-
tionships. Second, the property–biodistribution relationships 
are very complex. Assumption of linear relationship may be 
a simplification, at least for some organs. More complex, 
nonlinear equations might better describe the property–
biodistribution relationships. However, at the present stage, 
there is limited knowledge to determine the patterns of 
property–  biodistribution relationships, and an arbitrary 
selection of more advanced relationships may lead to misin-
terpretation of results. In fact, nonlinear relationships were 
also screened using nonlinear multivariate regression analysis 
(data not shown). However, the predicted biodistribution of 
PLGA-mPEG495 nanoparticles was not improved compared 
with that predicted by linear analysis.
It also needs to be noted that any models have limitations 
in application. The property–biodistribution relationships 
developed in this study were based on the specific properties for 
these PLGA and PLGA-mPEG nanoparticles. The relationships, 
very possibly, will change when other nanoparticle formulations 
are used. This model may be restricted from being directly 
applied to other nanoparticles, primarily because nanoparticle 
biodistribution is not determined solely by general properties 
such as size and surface charge, but also chemical components, 
such as PEG content in this study. The influence of chemical 
components on the in vivo performance of nanoparticles 
are significant, but far from well understood. This means 
nanoparticle formulations with different chemical components 
may have different biodistribution profiles, even if they have 
same size or surface charges. With this understanding, there 
may not be any universal property–biodistribution relationships 
available for nanoparticles of various chemical components, 
unless the effects of chemical components can be exclusively 
modeled across various materials. The same limitations of 
the model could be stated for numerous other nanoparticle 
properties not considered here, including   morphology and 
particles outside the size range studied here. The significance 
of this work is that it proved the feasibility of developing 
such relationships, and provides the general methodologies, 
which, the authors believe, can be applied universally to other 
nanoparticle formulations.
The correlation between nanoparticle properties and 
biodistribution may have far-reaching significance in nano-
particle research, including evaluation, development, and 
design. First, such relationships would help in understanding 
the contributions of each property to the in vivo behaviors 
of nanoparticles within the body. Second, the property–
biodistribution relationships can be used to predict the biodis-
tribution of nanoparticles based on their properties. Finally, 
these relationships may guide design and development of 
new nanoparticle formulations with controlled properties to 
obtain specific biodistribution profiles.
Conclusion
The biodistribution profiles of PLGA nanoparticles with 
various PEG content were mathematically described by a 
PBPK model. The model simulated the experimental results 
of tissue concentration-time curves quite well. The model 
also provided insights into the kinetics of nanoparticle in vivo 
distribution and the influence of multiple properties. The 
correlation between nanoparticle properties and biodistribu-
tion parameters enabled the relatively accurate prediction of 
biodistribution for another nanoparticle formulation. This is 
the first work using PBPK modeling to interpret the effects 
of multiple nanoparticle properties on their biodistribution. 
This illustrates the significance of a PBPK modeling approach 
for the building of nanoparticle property-distribution relation-
ships in vivo. The applications of this work are far-reaching 
including, but not limited to, nanoparticle toxicity assessment, 
rational carrier design for drug delivery and imaging, and data 
interpretation from in vivo bioimaging/biomarker systems.
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